Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

More than one million donated drugs risk expiring within nine months due to deep cuts in global aid, threatening treatment programmes for neglected tropical diseases in Africa.

A new study published in the Journal of Alzheimer’s Disease has found that the active ingredient in popular drugs like Ozempic and Wegovy may lower the risk of developing dementia. NBC News ...

Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared to patients taking another diabetes drug—empagliflozin. International ...

High-risk drug lab in the city centre Patrol officers of the 7th district police went to an apartment building in Erzsebetvaros to respond to a call from a member of the public concerning a pungent ...

The benefits of drug warranties extend beyond risk management. They can also serve as market differentiators in crowded therapeutic areas, especially where several drugs offer comparable efficacy.

LEHI, Utah, May 28, 2025 /PRNewswire/ -- Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare ...

Researchers in a new study found that the drug showed an ability to protect the brain in a certain way, which is a critical defense against Alzheimer’s disease.

QI Path is a category-defining risk intelligence platform that empowers organizations in regulated industries to proactively govern operational risk, ensure regulatory compliance, and accelerate ...

A new drug, developed and tested in mice, may protect the brain from the damage caused by Alzheimer’s and preserve memory and thinking skills.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. More ...

A new UVA study finds that HIV drugs like NRTIs may reduce Alzheimer's risk by 10% annually, suggesting potential for repurposing in dementia prevention.